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Schizophrenia and Alzheimer’s disease are two disorders that, while conceptualized as
pathophysiologically and clinically distinct, cause substantial cognitive and behavioral
impairment worldwide, and target apparently similar – or nearby – circuitry in regions such
as the temporal and frontal lobes. We review the salient differences and similarities from
selected historical, nosological, and putative mechanistic viewpoints, as a means to help
both clinicians and researchers gain a better insight into these intriguing disorders, for
which over a century of research and decades of translational development was needed
to begin yielding treatments that are objectively effective, but still very far from entirely
satisfactory. Ongoing comparison and “cross-pollination” among these approaches to dis-
orders that produce similar deficits is likely to continue improving both our insight into the
mechanisms at play, and the development of biotechnological approaches to tackle both
conditions – and related disorders – more rapidly and efficaciously.
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INTRODUCTION
Cognitive and behavioral dysfunction occurs both in Alzheimer’s
disease (AD) and in schizophrenia, and – differences aside – is
one of the most distinctive and disabling features of these oth-
erwise conceptually different disorders. Therefore, an assessment
of the differences and similarities in the cognitive impairment in
schizophrenia vs. AD is relevant for many reasons, including: (1)
both disorders are among the most prevalent neuropsychiatric
disorders worldwide, (2) the term démence précoce coined by the
French alienist Auguste Morel in 1853, which was then translated
as dementia praecox, by Pick in Prague (1) and then popularized
by Eugen Bleuler (2) in 1911 and, especially, by Emil Kraepelin
(3) still conjures a misleading association with the degenerative
dementias (4). In fact, although the term dementia praecox has
since fallen out of favor, it remains in the memory of both special-
ists and, in many cases, the public, and still evokes valid parallels
as well as easily understandable confusion and erroneous com-
parisons with and array of conditions that we now conceptualize
as nosologically distinct, i.e., the distinct types of Degenerative
Dementias, and (3) the increasingly better documented tendency
of most patients with schizophrenia to develop cognitive dysfunc-
tion and imaging evidence for brain degeneration over the years,
even if they go into remission and/or have a seemingly favor-
able response to treatment. This constitutes another important
feature in common with the dementias due to cerebral degenera-
tion, since the clinical manifestations of patients that have suffered
from schizophrenia eventually tend to blend and merge with the
array of symptoms in the dementias more prevalent in the elderly.
Since the latter phenomenon casts yet another layer of controversy
about the already confusing – and conflicting – hypotheses about
nosology in schizophrenia, it is both appropriate and necessary to
discuss this matter in sufficient detail to inform the efforts to help
develop innovative and transformative biotechnology to conquer
these and related disorders.
HISTORICAL OVERVIEW
The controversy over the appropriateness of the term dementia
praecox usually does not revolve around its attempt to capture
or subsume the rather vague concepts of “premature dementia”
and “precocious madness.” In that sense, many would agree that
Morel’s coinage does convey adequately the concept of a premature
dissolution of cognitive function, or at least an impairment of the
ability for cognitive integration. AD was characterized from the
start as a disorder of cognitive integration, with prominent psy-
chiatric features (5) and soon after its discovery it was postulated
that it represented a pre-senile condition (6). That latter feature –
abandoned only very gradually since the late 1970s – attempted to
position AD between the“premature”dementias (e.g., schizophre-
nia), and to justify the now nearly vanished distinction with the
dementias in “senility.” This is both because the concept of senil-
ity has become increasingly more elusive biologically, and because
clinical and histopathological differences could not be substanti-
ated comparing patients in their fourth through seventh decades
(5), although that may change as we become able to evaluate large
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numbers of much older patients (7). Be that as it may, it does not
call into question the concept that schizophrenia usually presents
earlier in life than AD, including most of the extremely rare cases
of early-onset so-called familial AD (early-to-mid third decade).
Historically, there was never a confusion about the use of the word
“dementia” in the sense of erroneously implying a strict similarity
with dementias of later onset, whether “pre-senile” or “senile.” In
fact, Bleuler never implied this, although he did advance the con-
cept that schizophrenia is a disorder from which no one recovers
(2), which was refuted by Kraepelin much later. Nevertheless, it
was Kraepelin, employing his careful analysis of large numbers of
patients, first in Dorpat and then in Heidelberg, that formulated
the notion that schizophrenia was primarily a “psychic degenera-
tive process”(1899) within which he distinguished several different
subclasses, including “dementia simplex” (roughly today’s simple
schizophrenia) (3). It is beyond the scope of this chapter to discuss
in depth the fact that, despite an agreement regarding the primacy
of the cognitive manifestations in schizophrenia, there are many
important differences between Bleuler’s and Kraepelin’s formu-
lation of the concept of dementia praecox. The key fact remains,
however, that early formulations of the concept of schizophre-
nia emphasized a notion of cognitive deterioration and relatively
relentless progressive deterioration, a concept that was eventually
restored after some six or more decades of predominance of psy-
choanalytic views that painted – unfortunately inaccurately – a
less dire prognosis over time.
COMPARISON BETWEEN THE CLINICAL MANIFESTATIONS
IN SCHIZOPHRENIA AND IN AD
Alzheimer’s disease usually begins with a progressive deterioration
in memory, and over time additional symptoms accrue that reflect
the involvement of other cognitive spheres. The latter symptoms
may include aphasia, apraxia, agraphia, and alterations in visu-
ospatial abilities (6, 8) and eventually a disintegration of virtually
every cognitive sphere. There are also a few well-documented cases
in which – uncharacteristically – instead of memory loss, the ini-
tial manifestation involves a different cerebral cortex-dependent
faculty, such as an aphasia, “posterior cortical atrophy,” or a right
parietal syndrome (9–17).
The bulk of the experimental evidence suggests very strongly
that this is a predominantly cerebrocortical disorder, first recog-
nized by the prescient statement of Alois Alzheimer himself (5) that
this is a disorder of the cerebral cortex. Within the general frame-
work of cortical involvement, however, there is a clear predilection
not only for certain regions of the cortex, but also for certain lay-
ers of this structure and, as is well known, for certain types of
neurons: pyramidal cells (18). Here, after reviewing briefly the
latter aspects, we end this section by focusing on a remarkable
but essentially ignored topic: the mounting evidence that there
is also a predilection for specific components of the hypothetical
anatomical and functional unit of the cerebral cortex, the so-called
cortical “module.” This relatively new pathophysiological concept
has key implications for the understanding of the disorder from
the integrative and systems neuroscience perspective (19). Such
viewpoint may permit a new synthesis with the inevitably – and
in fact, desirably – reductionist analysis of the disorder from the
molecular perspective, since it allows for an integration of these
two distinct levels of inquiry in order to better understand the
basis for normal and disordered cognitive function and behavior
in virtually all neuropsychiatric conditions (20, 21). Along these
lines, it would seem that – given the volume of information avail-
able – this novel paradigmatic view may eventually be applied to
the understanding and treatment of many other disorders charac-
terized by deterioration in cognition and behavior due to targeting
of the cerebral cortex, such as schizophrenia.
ALZHEIMER’S DISEASE AS A CEREBROCORTICAL PROCESS
Despite the broad variety of symptoms among patients – includ-
ing unusual presentations and even those that are extremely rare
such as aphasias and a right parietal lobe syndrome – it seems
reasonable to postulate that in virtually all cases the symptoms
reflect cerebrocortical dysfunction (5, 18–24). The vast major-
ity of studies also indicate that the main lesions situated in the
brain – i.e., senile plaques and neurofibrillary tangles – are situ-
ated predominantly in the cerebral cortex (5, 25). Furthermore,
even in those studies focusing on the subcortical involvement,
such as those in the nucleus basalis of Meynert (26), in the locus
ceruleus (27) or in the pulvinar nucleus of the thalamus (18),
the pathophysiological interpretation of the findings is invariably
made in terms of how they affect cortical function, and in no case
contradict the fundamental importance attributed to the cortical
lesions. Thus, it is postulated that lesions in the nucleus basalis of
Meynert are important because they deprive the cerebral cortex
of its cholinergic innervation (25), and that lesions in the pul-
vinar destroy cortico-thalamo-cortical circuits that interconnect
this nucleus with a vast territory in the association cortex, thus
compounding the functional impact of cortico-cortical discon-
nection in AD (18). There is virtually no information as to whether
such connections are targeted in schizophrenia, which is surprising
since such a phenomenon – whether due to anatomical damage or
“functional” mechanisms (e.g., synaptic failure without synaptic
degeneration) – would likely result in a dissolution of the integra-
tion of cortical functions that is presumably essential for normal
cognition and behavior.
These notions, combined with the relative absence of lesions
in the majority of subcortical regions – and especially in contrast
with many other dementing conditions in which the pathology
is situated predominantly (if not always exclusively) subcortically
(e.g., Parkinson’s disease dementia, Huntington’s disease, and Pro-
gressive Supranuclear Palsy) – support the contention that AD is
a cerebrocortical disconnection disorder (18, 28–32). This con-
cept has allowed some of us to focus many studies in which we
attempt to understand in detail the pathophysiology of the dis-
order, by analyzing in detail the topographic distribution of the
lesions in the cerebral cortex (23, 27, 33, 34). Such focus intends,
among other objectives, to understand the mechanisms under-
lying the disorder in terms of the circuits that are presumably
selectively affected, compared with circuits that tend to be rela-
tively spared, or are resistant to the degenerative process. Such a
perspective is rarely considered in parallel with that which tends
to dominate inquiry in this field today: i.e., the molecular factors
involved in the pathogenesis and pathophysiology of the disease.
Nevertheless, the analysis of the patterns of topographic distri-
bution of lesions in the disorder, which is in its infancy, adds
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an important dimension – i.e., that of Systems Neuroscience –
to the understanding of the pathophysiology of the condition.
Such a perspective is undoubtedly essential in the brain, which is
the organ with the broadest phenotypic diversity among its cells
in the entire organism, a diversity that cannot be subsumed, or
“reduced” to the molecular level alone. Therefore, it is not rea-
sonable to consider the role of any trophic or toxic agent – or
any other molecular factor affecting the expression of the clinical
phenotype – while ignoring the highly complex three-dimensional
organization of the brain. In fact, assuming that most of the vari-
ous cell types in the brain are exposed to the degenerative process,
the bulk of the neuropathological studies demonstrate that specific
types of cells are highly susceptible, whereas others are remark-
ably resistant to the disease (Figure 1). Therefore, the diversity
of the potential targets contrasts sharply with the relatively small
array of apparently affected cells, a fact that defies explanation to
this date.
The great majority of studies on AD reveal a considerably
stereotyped pattern of involvement in the cortex: regions most
affected include the entorhinal cortex (Brodmann’s area 28), the
perirhinal cortex (area 35), the subjacent hippocampus and the
temporopolar cortex (area 38) (22–24, 34). Compared to these
areas, the rest of the association cortex develops an intermedi-
ate density of lesions, whereas the primary cortices – both motor
and sensory – develop the lowest density of neurofibrillary tangles
(Figure 2). It is important to emphasize, however, that this notion
is predicated primarily on the density of neurofibrillary tangles,
whose distribution is felt by many to correlate best with the level
of cognitive deterioration (35–37), although it has been shown
that primary sensory cortices have a high density of senile plaques
(38) which is in fact much higher than that in medial temporal
regions that are widely perceived as severely affected (22). Apart
from this gross overall topographic pattern, there is also a distinct
laminar predilection in the distribution of the lesions (Figure 1).
This pattern applies both to allocortical and to iso(neo)cortical
regions, and consists generally in a higher density of lesions in lay-
ers from which cortico-cortical projections originate (layers II/III
in the neocortex), as compared with layers that receive projec-
tions from subcortical regions (I and IV) or layers from where
feedback cortico-subcortical projections originate (VI). Such a
pattern permits postulating that the disposition of the lesions
explain the cortical dysfunction in terms of a disconnection result-
ing from the disruption of cortico-cortical connectivity (32, 38), as
already discussed above and summarized in Figure 1. In addition
to such regional and laminar patters of selective targeting, there is
mounting evidence that there is also selective targeting of supracel-
lular arrays that constitute the hypothetical functional units of the
cerebral cortex, often called “modules” or “hypercolumns,” which
we have reviewed in detail recently (19). Therefore, as befits the
complexity of the cerebral cortex, there is an intricate pattern of
selective vulnerability vs. sparing of closely intertwined cells, and
groups of cells, that is only beginning to become apparent, but that
FIGURE 1 | Schematic representation of the neuropathology of
Alzheimer’s disease, based on the selective laminar distribution of senile
plaques and neurofibrillary tangles and the circuitry they target. The
blocks represent different regions of the cerebral cortex, in which the Roman
numerals indicate cortical layers and letters identify main types of neurons
according to the key in the figure itself. Neurons selectively targeted in AD are
the medium-sized pyramidal neurons making cortico-cortical connections
(labeled as “C”) and the corticipetal neurons in the pulvinar nucleus of the
thalamus that effect cortico-thalamo-cortical connections (labeled as “A”). By
contrast, large pyramidal neurons in layer V (labeled as “D”), corticothalamic
projection neurons in layer VI (labeled as “B”), and layer IV granule cells
(labeled as “E”) are much less affected or spared. The putative involvement of
local circuit neurons (labeled as “F”) is less well understood. Modified from
Kuljiš (21).
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FIGURE 2 | Pseudocolor rendering of the relative density of neurofibrillary tangles (NFT) in Alzheimer’s disease, where warm colors represent higher
densities and cold colors progressively lower lesion densities. Modified from the work of Arnold and collaborators (22), and from Kuljiš (33).
needs to be better understood to achieve an adequate understand-
ing of the mechanisms governing the targeting of molecules, cells,
cellular arrays, and cerebrocortical regions in AD.
SCHIZOPHRENIA AS “THE GRAVEYARD OF
NEUROPATHOLOGISTS”
Many believe that schizophrenia and related disorders result
from alterations in brain circuits (39). Yet, this probably cor-
rect assumption lacks a concrete factual demonstration – hun-
dreds of unverified neuropathological claims non-withstanding –
and is in stark contrast with the relative wealth of informa-
tion on the neuropathology of AD because virtually nothing
claimed about histopathological observations in schizophrenia
has survived efforts at independent verification or corrobora-
tion. This justifies Stevens’ admonition about schizophrenia being
“the graveyard of neuropathologists” (40, 41), which unfortu-
nately continues to be the case decades since its enunciation. In
fact, arguably the only widely accepted, consistent morphological
alterations have been found by in vivo imaging, that consist in a
reduction in gray matter, enlargement of the ventricles of the brain,
and focal alterations in the white matter (42–44). This is hardly
specific, much less pathognomonic, and is perhaps consistent with
the increasingly popular syndromatic – as opposed to a unique, or
“sole disease” – view of the disorder (45), which would be consis-
tent with the lack of a truly unique and unanimously agreeable
cellular and molecular neuropathology. Be that as it may, it justi-
fies the still vaguely articulated perception that schizophrenia is a
disease of the cerebral cortex (39).
To many, this might appear as a profoundly unsatisfying expla-
nation, because it may imply that it is impossible to “pin down”
schizophrenia to a specific disorder of one cell, one molecule, or
one brain circuit, among other possibilities that may seem better
suited to present conventions to develop a therapeutic armamen-
tarium of modern Neuroscience. However, while the identification
of a unique and consistent defect at any level – circuit, neural cell,
or molecule – might facilitate enormously the rational design and
development of treatments for any disease, nothing precludes the
development and testing of novel agents for clinical syndromes – as
opposed to diseases – which may be the best approach for schiz-
ophrenia. However, whether the condition is a syndrome due to
many individually variable “factors” or “causes,” or a disease due to
one and only one cause has profound implications for the design
of rational strategies to pursue innovative treatments by means of
drugs or other avenues.
The dopamine hypothesis’ origin provides an example of just
such a situation, since it was formulated after the empirical
observation that chlorpromazine improves the condition(s), and
well before a rationale could be put together for the therapeu-
tic effect based on what remained – and still remains – to be
learned about that neurotransmitter and its roles in health and
disease (46). The possibility that the seemingly logical focus there-
after on monoamine pathway-modifying pharmacological agents
might have been inaccurate – from the pathophysiological per-
spective – does not negate the validity of searching for agents
that maximize the benefits of chlorpromazine, while mitigating
the potential for side effects. In fact, there are many lines of
evidence that make it obvious that there’s more than a dopamin-
ergic mechanism at play in schizophrenia, such as indications that
there are also serotoninergic and glutamatergic defects involved
as well (47–49), and there is also mounting evidence that there
may be developmental alterations – which are not confined to
the monoaminergic system – that either increase the risk or may
even cause schizophrenia (50–53). In the latter (i.e., “develop-
mental”) formulation, the clinical syndrome would be merely the
symptomatic manifestation of a mild developmental disorder that
manifests in the last phase of the brain’s development, i.e., as indi-
viduals undergo the transition from adolescence to adulthood, yet
the fact that the clinical syndrome can occur well after (45), or even
before (50) the adolescence-to-adulthood transition underscores
the near certainty that this is not simply a sole disorder of brain
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maturation – however broadly one may one to define it – but a clin-
ical syndrome that can occur as the result of many factors/causes,
and not only at the very adolescence-to-adulthood interface.
Be that as it may, for the purposes of the present discussion,
suffice it to say that there is a consensus that, like AD, schizophre-
nia targets mainly the cerebral cortex (Table 1) (39, 44, 45, 51).
Accordingly, as mentioned at the very beginning, this warrants
not only comparing these disorders both in terms of similarities
and differences, but also in terms of the nosological dilemmas they
present. The latter is not merely an “academic” exercise – in the
often pejorative sense that this term is nearly synonymous with
“useless” – but, on the contrary, has profound implications for
how we conceptualize these diseases etiologically and pathophysi-
ologically, which has extremely tangible and materially impactful
consequences, among other things in the choice of biotechnolog-
ical development investments we make to conquer them. In that
latter sense alone, the difference amounts to millions every year, of
whatever national currency is considered in terms of expenditures
in health care.
CAVEATS ON THE SUSCEPTIBILITY OF COMPARISONS
BETWEEN SCHIZOPHRENIA AND AD DUE TO NOSOLOGICAL
DILEMMAS
The “sporadic” (i.e., non-familial) form of the AD syndrome
(sADs, where the first “s” is for “sporadic,” and the second “s” is for
“syndrome”) is by far the most common form of this disorder, and
appears to result from a more or less individually unique set of
converging risk factors, inadequately counterbalanced by a set of
hypothetical protective factors that is also relatively unique to the
individual affected (20, 21, 54, 55). We have recently postulated
(56) that these sets of opposing factors operate over decades –
primarily (i.e., pathogenically) or secondarily (i.e., as a “common
final pathway” that requires prior events) – to target the so-called
“polydendrocytes,”a.k.a. beta astrocytes and the“fourth neuroglial
type,” a relatively recently discovered (57, 58) and subsequently
confirmed type of neural cell (59–62). We have re-designated
them as the “Fourth Element” cell (4EC) following the tradition
established by Santiago Ramón y Cajal when he made a distinc-
tion between neurons, macroglia, and all other types of cells in
Table 1 | A simplified list of selected similarities and key differences between Alzheimer’s disease and schizophrenia.
Alzheimer’s disease Schizophrenia
Etiology Unknown Unknown
Brain regions targeted Cerebral cortex including hippocampus, basal
forebrain, pulvinar nucleus of the thalamus
Prefrontal cortex, hippocampus, and temporal
neocortex
Cognitive impairment Memory usually followed by additional cognitive
and behavioral spheres of functioning
Impaired cognitive and behavioral integration, not
usually preceded by isolated memory impairment
Average age at onset Sixth decade and beyond Early adulthood
Main neurotransmitters implicated Acetylcholine Dopamine, serotonin, glutamate
Reduced lifespan Yes Yes
Tendency for substance abuse No Yes
Additional comorbidities Depression, anxiety Depression, anxiety
Hallucinations, delusions Yes Yes
Social withdrawal, poor hygiene, motivation,
and judgment
Yes Yes
Catatonia Very infrequent Rarely present (subtype)
Social withdrawal, irritability, dysphoria Yes Yes
Psychosis More likely in advanced stages More likely in early stages
Remission possible No Yes
Developmental basis proposed No Suspected
Accepted evidence for cerebral degeneration Precedes clinical manifestations Occurs years or decades after symptom onset
Association with substance abuse/misuse No Yes
First-line treatment Cholinesterase inhibitors, memantine Antipsychotics
Accepted histopathological features Yes No
Biomarker(s) available Noa No
aAlthough literally dozens are proposed, but none accepted for clinical diagnosis.
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the brain, and lumped the latter types of cell into a “Third Ele-
ment” (63). Pío del Río Hortega subsequently discovered – and
named – what we know today as the microglia from among the
Third Element employing a battery of silver carbonate impregna-
tion methods. Modern technology reconfirmed del Río Hortega’s
discoveries, and demonstrated that altered forms of microglia par-
ticipate in the pathology of AD, since they are a key component
of senile plaques (64–67) and other lesions (67). To the best of
our knowledge, it has not been proposed before that schizophre-
nia results from targeting the 4EC, yet there seems to be no reason
precluding such a possibility, which, of course, needs to be assessed
scientifically. Part of the reasons to pursue such an assessment is
precisely to establish yet another parameter for comparison with
AD, unencumbered by the titillating possibility that 4E targeting
in schizophrenia might be the long-sought but elusive “cause” of
the disorder. The latter will obviously necessitate experimental
evaluation, which is barely underway.
CAVEATS ON A CELLULAR-LEVEL FORMULATION
Given the ongoing dramatic changes in the distinction between
neurons and glial cells in the brain, the above proposal that 4EC
are pivotally involved in AD and schizophrenia defies the former
notion that the targeted element(s) can be conceptualized simplis-
tically as neurons vs. macroglia vs. microglia, vs. other cells that
are not of a neural lineage. In fact, considering the still unresolved
nature of 4EC as precursors or variants of oligodendrocytes, their
near-neuronal attributes (e.g., synapses and the participation on
glutamatergic and GABAergic neurotransmission) and their fea-
tures in common with “conventional” astrocytes, their postulated
primary, even pathogenic, involvement in AD blurs the previously
unassailable distinction among all conventional cell types in AD.
Even if the present proposal about the predominant targeting of
4EC in AD does not survive experimental testing, it casts doubt on
the ability to postulate targeting mechanisms based exclusively on
neuronal vs. glial phenotypes. Thus, it is also possible that it is not
specific cell types, but key attributes shared between neuronal and
non-neuronal cells that are targeted early on in the disease process,
if this process attacks first – or in any way selectively – neural cells.
Similar considerations apply to schizophrenia, in which, as stated
in the preceding section, the characterization of the possible par-
ticipation of 4EC has barely begun solely by stating the possibility
of such a mechanism.
THE INNOVATION GAP AND TRANSLATIONAL
APPLICATIONS TO THE PREVENTION AND TREATMENT OF
AD AND SCHIZOPHRENIA
Progress in conquering AD, schizophrenia, and related disorders
is hampered by the so-called Innovation Gap (IG), which is a
collection of challenges that includes: (a) the fact that the num-
ber of approved treatments has not increased despite substantial
increments in the investment toward the discovery and testing
for this purpose over decades, (b) the frequent lack of predictive
power for the efficacy in humans of the outcomes of testing in
so-called “models” of the disorder, and (c) in the case of AD, the
failure of all trials published to date based on the overwhelmingly
dominant amyloid hypothesis of AD pathogenesis (20, 21). If the
4EC hypothesis is correct, it would open an essentially unexplored
avenue for research and treatment development that could have
a powerful effect in overcoming the IG. Similar challenges apply
to schizophrenia, given the shared lack of an understood etiology
and pathophysiology, and despite the larger number of therapeu-
tic agents available since these – like in AD – palliate but do not
“cure” the disorder.
A recent report provides powerful evidence that it may now
possible to predict the outcome of patients at risk of developing
AD, by measuring putative markers of the disorder that include
β-amyloid and both total and phosphorylated tau protein in the
cerebrospinal fluid (68). However, markers with proven diagnos-
tic value do not presently include indicators of inflammation,
macroglial alterations, and, much less, 4EC involvement, although
there are numerous reports suggesting – but not proving – that
the former may also be of diagnostic value (69–73). Given the
probable multifactorial nature of sADs (54), it is likely that an
array of markers addressing different mechanisms involved in
the condition may help to: (1) increase the sensitivity and speci-
ficity of the tests under development, (2) discern subtypes of
patients in which different mechanisms mediate a similar cog-
nitive impairment syndrome, and (3) predict and monitor the
response to various alternative mechanism-selective treatments.
Therefore, whether the hypothetical 4EC mechanism proposed
here is universal, or unique to certain groups of patients, research
aimed at testing this hypothesis may lead to the implementation
of assays for 4EC involvement by cerebrospinal fluid analysis, or
blood-borne indicators of 4EC involvement, or in vivo imaging
assessment of such involvement (with ligands for 4EC) – or a
combination of these – as well as a more refined histopatho-
logical assessment for patients with Mild Cognitive Impairment
and dementia postmortem. The above considerations are rele-
vant also to our recent assessment of the intersection of the
epidemics of dementia and diabetes, since this is one additional
situation in which the elucidation of the targeted vs. spared or
disease-resistant elements is essential to move beyond conflicting
interpretations of the same or closely related experimental obser-
vations (74). Very similar considerations apply to schizophrenia,
given the equivalent lack of biomarkers both to make the diagno-
sis unencumbered by clinical observations, as well as to measure
the efficacy of the treatments and to determine whether they
impact the long-term prognosis of individual patients (45, 75).
This dilemma includes, but is not limited to the high prevalence
of metabolic syndrome and diabetes associated with the use of
antidepressants and antipsychotics in schizophrenia (76), which,
like in AD (74), probably interact with the original mechanisms
responsible for brain dysfunction and is quite likely to influence
the well-documented tendency for patients with schizophrenia
to continue to deteriorate cognitively, and certainly prematurely,
even now that their long-term survival has improved with better
treatment (45).
It has not escaped our attention that casting hypotheses on
the primary targeting mechanisms causing AD and schizophre-
nia in terms of one or another cell type – or cellular compo-
nent, such as synapses – may be narrow-minded and ultimately
inadequate. In fact, given: (1) the seemingly “unconventional”
nature of 4EC, which share cytological and molecular features
with neurons, macroglia, and oligodendrocytes, but are neither,
Frontiers in Psychiatry | Schizophrenia February 2014 | Volume 4 | Article 119 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kuljiš et al. Cerebral dysfunction schizophrenia and Alzheimer’s disease
(2) the evidence that markers previously felt to be unique to neu-
rons – such as doublecortin – or macroglia – such as S100B – are
expressed by a variety of other cell types (77, 78), and (3) that
the S100B/RAGE-mediated activation of microglia (79) indicates
there may be and inextricable interaction between 4EC, macro-
and microglia in the genesis of brain inflammation that initially
triggers neurodegeneration (54, 80, 81), it may be difficult to
discern between a primary/initial macro- vs. microglial trigger
of AD or schizophrenia. This challenge is in fact compounded
by the 4EC hypothesis, since 4EC share properties with several
neural cell types. However, it would seem that casting such a
hypothesis in terms of a putative primary involvement of 4EC
is scientifically testable, and provides a heuristically useful coun-
terbalance to the presently massive – if appropriate – attention
to the suspected role of microglia in the early mechanisms medi-
ating AD and schizophrenia (54, 66, 67, 82). This will require
further characterization of 4EC in both the normal and diseased
human and non-human brain, to approach the level of sophisti-
cation with which it is possible to study today the involvement of
more “conventional” types of cell in the brain and other organs.
None of the above hypothetical scenarios are contradictory or
incompatible with the eventual (i.e., secondary) dysfunction, fol-
lowed by the degeneration and death of neurons, as the final
mediator of the clinical manifestations of AD, schizophrenia, and
related disorders as proposed by many authors, including our-
selves (19–21, 54, 74, 83). Such secondary events include also
inflammation and the (intra- and extra-cellular) accumulation
of pathological forms of amyloid and tau proteins (in AD, since
it is unknown whether this occurs in schizophrenia), regard-
less of whether these are cast as disease-compounding, or ulti-
mately ineffective or counterproductive attempts at cellular and
molecular defense.
FINAL CONSIDERATIONS
It is important to remark that future research in both schiz-
ophrenia and AD is likely to benefit from substantial refine-
ments in non-pharmacological treatments available today, which
are unfortunately poorly standardized at present, and, therefore,
not regimented into accepted treatments covered by virtually all
forms of health insurance. Perhaps the best example of such a
need is physical exercise, for which there is a growing body of
literature indicating clearcut benefits not only in mild cogni-
tive impairment and AD (84), but also in schizophrenia (85).
The significant elevation of brain-derived neurotrophic factor
(BDNF) caused by physical exercise – which has also been used
as a surrogate marker for “neuroplasticity” – is among the likely
mediators of such experimentally assessed benefits, which have
been corroborated repeatedly and independently, along with as
yet much less well standardized attempts at cognitive remedia-
tion (a.k.a. “cognitive retraining”) and various forms of social,
sensory, and motor stimulation. These interventions appear to
synergistically improve the condition of patients with both con-
ditions (AD and schizophrenia), in addition to pharmacological
agents. Therefore, while never ignoring or neglecting the need to
continue searching for the hypothetical “cause(s)” of these dis-
orders, and refining our intellectual and therapeutic constructs
for them as clinical syndromes vs. true diseases, we should con-
tinue to develop interventions such as exercise, various forms
of sensory stimulation, and cognitive retraining with the inten-
tion that they become a mainstay of treatment alongside more
“conventional” (e.g., pharmacological) approaches. This is indis-
pensable, since these novel forms of intervention appear to be
strongly beneficial, and perhaps overall much less expensive and
devoid of severe side effects than seemingly more “conventional”
approaches to molecular therapy that, in any case, remain only
palliative and unsatisfactory in the eyes of virtually all practi-
tioners. This approach should ideally be part and parcel of the
ongoing re-examination of the field of neurodegenerative and
neuropsychiatric disorders, which has as a common theme the
dire need to reinvigorate the intellectual framework to establish
causality, etiologies, and pathophysiology in an integrative, multi-
disciplinary fashion, beyond the molecular level alone (20, 21, 86).
Taken together, these considerations emphasize the need to con-
tinuously – and increasingly – “compare notes” among specialists
in AD and schizophrenia, as well as many other closely related
fields. This exchange will likely continue to result in intellectual
“cross-pollination” that will facilitate our cruising the arduous
road to conquer these and many other related neuropsychiatric
disorders.
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